IP Verse

Pharmaceutical Compositions For The Treatment Of Cftr Mediated Diseases - EP2914248

The patent EP2914248 was granted to Vertex Pharmaceuticals Incorporated on Oct 18, 2023. The application was originally filed on Nov 1, 2013 under application number EP13792149A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP2914248

VERTEX PHARMACEUTICALS INCORPORATED
Application Number
EP13792149A
Filing Date
Nov 1, 2013
Status
Patent Maintained As Amended
Sep 15, 2023
Grant Date
Oct 18, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJun 4, 2019TER MEER STEINMEISTER & PARTNER -

Patent Citations (51) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2003144257
DESCRIPTIONUS2004105820
DESCRIPTIONUS2005164973
DESCRIPTIONUS2006035943
DESCRIPTIONUS2006148863
DESCRIPTIONUS2006148864
DESCRIPTIONUS2010074949
DESCRIPTIONUS6992096
DESCRIPTIONUS7202262
DESCRIPTIONUS7495103
DESCRIPTIONUS7741321
DESCRIPTIONUS8247436
DESCRIPTIONUS8507534
DESCRIPTIONWO2004028480
DESCRIPTIONWO2004080972
DESCRIPTIONWO2004091502
DESCRIPTIONWO2004110352
DESCRIPTIONWO2004111014
DESCRIPTIONWO2005035514
DESCRIPTIONWO2005049018
DESCRIPTIONWO2005094374
DESCRIPTIONWO2005120497
DESCRIPTIONWO2006002421
DESCRIPTIONWO2006044456
DESCRIPTIONWO2006044502
DESCRIPTIONWO2006044503
DESCRIPTIONWO2006044505
DESCRIPTIONWO2006044682
DESCRIPTIONWO2006099256
DESCRIPTIONWO2006101740
DESCRIPTIONWO2006110483
DESCRIPTIONWO2006127588
DESCRIPTIONWO2007044560
DESCRIPTIONWO2007056341
DESCRIPTIONWO2008135557
DESCRIPTIONWO2009073757
DESCRIPTIONWO2009074575
DESCRIPTIONWO2009150137
DESCRIPTIONWO2010019239
DESCRIPTIONWO2011028740
DESCRIPTIONWO2011079087
DESCRIPTIONWO2011113894
DESCRIPTIONWO2012035158
INTERNATIONAL-SEARCH-REPORTWO2009073757
INTERNATIONAL-SEARCH-REPORTWO2010019239
INTERNATIONAL-SEARCH-REPORTWO2013112804
OPPOSITIONUS2011256220
OPPOSITIONWO2009073757
OPPOSITIONWO2010019239
OPPOSITIONWO2010037066
OPPOSITIONWO2012147101

Non-Patent Literature (NPL) Citations (24) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- CUTTING, G. R. ET AL., NATURE, (1990), vol. 346, pages 366 - 369-
DESCRIPTION- DALEMANS ET AL., NATURE LOND., (1991), vol. 354, pages 526 - 528-
DESCRIPTION- DALEMANS, W.; BARBRY, P.; CHAMPIGNY, G.; JALLAT, S.; DOTT, K.; DREYER, D.; CRYSTAL, R.G.; PAVIRANI, A.; LECOCQ, J-P.; LAZDUNSKI, M, NATURE, (1991), vol. 354, pages 526 - 528-
DESCRIPTION- DEAN, M. ET AL., CELL, (1990), vol. 61, pages 863 - 870-
DESCRIPTION- GALIETTA, L.J.V.; LANTERO, S.; GAZZOLO, A.; SACCO, 0.; ROMANO, L.; ROSSI, G.A.; ZEGARRA-MORAN, O., IN VITRO CELL. DEV. BIOL., (1998), vol. 34, pages 478 - 481-
DESCRIPTION- GONZALEZ, J. E.; R. Y. TSIEN, "Voltage sensing by fluorescence resonance energy transfer in single cells", BIOPHYS J, (1995), vol. 69, no. 4, pages 1272 - 80, XP000961694-
DESCRIPTION- KEREM, B-S ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 8447 - 8451-
DESCRIPTION- KEREM, B-S. ET AL., SCIENCE, (1989), vol. 245, pages 1073 - 1080-
DESCRIPTION- MARSHALL, "Atomization and Spray-Drying", CHEM. ENG. PROG. MONOGR. SERIES 2, (1954), vol. 50-
DESCRIPTION- PASYK; FOSKETT, J. CELL. BIOCHEM., (1995), vol. 270, pages 12347 - 50-
DESCRIPTION- QUINTON, P. M., FASEB J., (1990), vol. 4, pages 2709 - 2727-
DESCRIPTION- RAE, J.; COOPER, K.; GATES, P.; WATSKY, M., J. NEUROSCI. METHODS, (1991), vol. 37, pages 15 - 26-
DESCRIPTION- The United States Pharmacopeia, (1995), pages 1843 - 1844-
DESCRIPTION- GONZALEZ, J. E.; R. Y. TSIEN, "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer", CHEM BIOL, (1997), vol. 4, no. 4, doi:doi:10.1016/S1074-5521(97)90070-3, pages 269 - 77, XP000961796
DESCRIPTION- GONZALEZ, J. E.; K. OADES ET AL., "Cell-based assays and instrumentation for screening ion-channel targets", DRUG DISCOV TODAY, (1999), vol. 4, no. 9, doi:doi:10.1016/S1359-6446(99)01383-5, pages 431 - 439, XP001026838
INTERNATIONAL-SEARCH-REPORT- BOYLE, MP ET AL., "VX-809, an investigational CFTR corrector, in combination with VX-770, an investigational CFTR potentiator, in subjects with CF and homozygous for the F508del-CFTR mutation", PEDIATRIC PULMONOLOGY, (20111001), vol. 46, no. S34, ISSN 1099-0496, page 287, XP002719045 [A] 1-48 * abstract *-
INTERNATIONAL-SEARCH-REPORT- "Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous for the F508del-CFTR Mutation", INTERNET CITATION, (201103), pages 1 - 4, URL: http://clinicaltrials.gov/archive/NCT01225211/2011_03_01, (20120726), XP002680870 [A] 1-48 * page 1 * * page 3, lines 1-4 *-
OPPOSITION- Badrul A. Chowdhury, "Summary Review of regulatory action", CENTER FOR DRUG EVALUATION AND RESEARCH, (20150625), XP055607267-
OPPOSITION- MERK et al., "Neue Ansätze bei Mukoviszidose", Pharmazeutische Zeitung, (20110913), URL: https://www.pharmazeutische-zeitung.de/ausgabe-372011/neue-ansaetze-bei-mukoviszidose/-
OPPOSITION- MERK et al., "Neue Ansätze bei Mukoviszidose", Pharmazeutische Zeitung, (20110913), URL: https://www.pharmazeutische-zeitung.de/ausgabe-372011/neue-ansaetze-bei-mukoviszidose/, XP055607266-
OPPOSITION- ROWE et al., "Progress in cystic fibrosis and the CF Therapeutics Development Network", Thorax, (20190900), vol. 67, no. 10, pages 889 - 890-
OPPOSITION- VERTEX, "Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference", Press-Release, (20121011), pages 1 - 4-
OPPOSITION- VERTEX, "Data from Phase 2 Combination Study of VX-809 and Ivacaftor in People with Cystic Fibrosis Who Have the Most Common Genetic Mutation (F508del) Presented at North American Cystic Fibrosis Conference", Press-Release, (20121011), pages 1 - 4, XP055607268-
OPPOSITION- ROWE et al., "Progress in cystic fibrosis and the CF Therapeutics Development Network", Thorax, (20190900), vol. 67, no. 10, pages 889 - 890, XP055607264

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents